Page last updated: 2024-12-05

2-phenylbenzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Phenylbenzimidazole is a heterocyclic compound with a benzimidazole core substituted with a phenyl group at the 2-position. It is known for its potential biological activities, including anti-cancer, anti-inflammatory, and antimicrobial properties. The synthesis of 2-phenylbenzimidazole often involves a condensation reaction between o-phenylenediamine and benzaldehyde. This compound is studied extensively due to its potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science.'

2-phenylbenzimidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12855
CHEMBL ID153535
SCHEMBL ID105095
MeSH IDM0302080

Synonyms (69)

Synonym
BIDD:GT0186
AC-7237
5-23-08-00437 (beilstein handbook reference)
unii-cb9zj140sb
cb9zj140sb ,
2-phenyl-1h-1,3-benzodiazole
cid_12855
bdbm3789
BB 0241957
benzimidazole, 2-phenyl-
gainex
phenzidol
phenizidole
nsc-251956
2-phenylbenzimidazole
nsc251956
phenzidole
716-79-0
AF-407/01228019
nsc 251956
einecs 211-939-2
brn 0007087
1h-benzimidazole, 2-phenyl-
2-phenyl-1h-benzimidazole
inchi=1/c13h10n2/c1-2-6-10(7-3-1)13-14-11-8-4-5-9-12(11)15-13/h1-9h,(h,14,15
2-phenylbenzimidazole, 97%
MLS000701325
smr000526282
STK227880
CHEMBL153535
AKOS000275572
P1105
HMS1728H19
NCGC00247174-01
1h-benzimidazole, phenyl-
BBL000186
2-phenylbenzimdazole
2-phenyl-1h-benzo[d]imidazole
2-phenyl-1h-benzoimidazole
HMS2235H23
FT-0613322
n,n'-benzenyl-o-phenylenediamine
2-phenyl-1h-benzimidazole [mi]
F0853-0315
HMS3372F02
AB00876270-08
phenyl benzimidazole
2-phenyl-benzimidazole
phenylbenzimidazole
2-phenyl benzimidazole
SCHEMBL105095
mfcd00005592
SY005301
cas-716-79-0
dtxsid5052460 ,
NCGC00357026-01
dtxcid2031033
tox21_303711
Q-101090
g 570
Z50129842
CS-W010651
AS-11952
BCP27606
AMY22061
BRD-K90551865-001-05-1
O10849
Q27275387
EN300-16230

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" PBI can absorb the UV portion of the solar light and undergo a series of light-induced reactions to cause adverse effects in humans."( Light-induced cytotoxicity and genotoxicity of a sunscreen agent, 2-phenylbenzimidazole in Salmonella typhimurium TA 102 and HaCaT keratinocytes.
Gilley, S; Mosley, CN; Wang, L; Wang, S; Yu, H, 2007
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (41)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency6.60340.007215.758889.3584AID1224835; AID588342
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency56.23410.100020.879379.4328AID588456
BRCA1Homo sapiens (human)Potency8.91250.89137.722525.1189AID624202
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.80330.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency5.17140.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency11.58210.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency36.38070.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency11.32930.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency3.85710.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.63810.001022.650876.6163AID1224838; AID1224839; AID1224893
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.64380.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.32040.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency9.68850.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.17730.000229.305416,493.5996AID1259244; AID1259248
pyruvate kinaseLeishmania mexicana mexicanaPotency12.58930.398113.744731.6228AID1721; AID1722
caspase-3Homo sapiens (human)Potency3.85710.013326.981070.7614AID1346978
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency31.62280.036619.637650.1187AID2100
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency2.59290.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency7.94333.548119.542744.6684AID743266
histone deacetylase 9 isoform 3Homo sapiens (human)Potency2.34380.037617.082361.1927AID1259364; AID1259388
ras-related protein Rab-9AHomo sapiens (human)Potency1.58490.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency19.95260.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.14130.00798.23321,122.0200AID2546
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.70790.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency1.08710.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency1.08710.001551.739315,848.9004AID1259244
Endothelin receptor type BRattus norvegicus (Norway rat)Potency12.58930.562315.160931.6228AID1721
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency12.58930.562315.160931.6228AID1721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)IC50 (µMol)54.95417.40007.80008.2000AID38394
Platelet-derived growth factor receptor betaMus musculus (house mouse)IC50 (µMol)50.00000.00180.75529.5000AID161099
Platelet-derived growth factor receptor betaHomo sapiens (human)IC50 (µMol)50.00000.00060.80078.5000AID1795561
Fibroblast growth factor receptor 1Homo sapiens (human)IC50 (µMol)50.00000.00020.942010.0000AID1795561; AID73439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)195.00000.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC50300.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (100)

Processvia Protein(s)Taxonomy
signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in vasculogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
aorta morphogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of MAP kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of mitotic nuclear divisionPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphatidylinositol metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in coronary angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor betaHomo sapiens (human)
smooth muscle cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular mesangial cell proliferation involved in metanephros developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium ion importPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of DNA biosynthetic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 1Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 1Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 1Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 1Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
organ inductionFibroblast growth factor receptor 1Homo sapiens (human)
neuron migrationFibroblast growth factor receptor 1Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
sensory perception of soundFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
gene expressionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase C activityFibroblast growth factor receptor 1Homo sapiens (human)
regulation of phosphate transportFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 1Homo sapiens (human)
cell projection assemblyFibroblast growth factor receptor 1Homo sapiens (human)
embryonic limb morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 1Homo sapiens (human)
neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 1Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
outer ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
middle ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
chordate embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAP kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusFibroblast growth factor receptor 1Homo sapiens (human)
regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
phosphatidylinositol-mediated signalingFibroblast growth factor receptor 1Homo sapiens (human)
paraxial mesoderm developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of lateral mesodermal cell fate specificationFibroblast growth factor receptor 1Homo sapiens (human)
cell maturationFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
stem cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 1Homo sapiens (human)
calcium ion homeostasisFibroblast growth factor receptor 1Homo sapiens (human)
cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
auditory receptor cell developmentFibroblast growth factor receptor 1Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingFibroblast growth factor receptor 1Homo sapiens (human)
vitamin D3 metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
diphosphate metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
cementum mineralizationFibroblast growth factor receptor 1Homo sapiens (human)
stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of fibroblast growth factor productionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replicationFibroblast growth factor receptor 1Homo sapiens (human)
response to sodium phosphateFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of parathyroid hormone secretionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisFibroblast growth factor receptor 1Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligandFibroblast growth factor receptor 1Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
protein kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein tyrosine kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet activating factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor beta-receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
signaling receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
enzyme bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein kinase bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 1Homo sapiens (human)
protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 1Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 1Homo sapiens (human)
SH2 domain bindingFibroblast growth factor receptor 1Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 1Homo sapiens (human)
receptor-receptor interactionFibroblast growth factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor betaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
focal adhesionPlatelet-derived growth factor receptor betaHomo sapiens (human)
membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
apical plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmic vesiclePlatelet-derived growth factor receptor betaHomo sapiens (human)
lysosomal lumenPlatelet-derived growth factor receptor betaHomo sapiens (human)
intracellular membrane-bounded organellePlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor betaHomo sapiens (human)
extracellular regionFibroblast growth factor receptor 1Homo sapiens (human)
nucleusFibroblast growth factor receptor 1Homo sapiens (human)
cytosolFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
membraneFibroblast growth factor receptor 1Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 1Homo sapiens (human)
receptor complexFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1795561Kinase Inhibition Assay from Article 10.1021/jm9804681: \\Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.\\1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
AID755672Antibacterial activity against Staphylococcus aureus after 24 hrs by agar dilution method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID50436Compound tested for contractility in isolated cat papillary muscle at 10 e-5 M.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID50434Compound tested for contractility in isolated cat papillary muscle at 10 e-4 M.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID670504Growth inhibition of Chlamydia pneumoniae at 10 uM2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Conformation study of 2-arylbenzimidazoles as inhibitors of Chlamydia pneumoniae growth.
AID1130737Anthelmintic activity against Hymenolepis nana infected in CF1 mouse assessed as clearance of worm burden assessed as clearance of worm burden at 0.2% dosed through diet for 4 days dosed 16 days post infection by press-plate technique1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiparasitic agents. 3. Synthesis and anthelmintic activities of novel 2-pyridinyl-5-isothiocyanatobenzimidazoles.
AID352317Antimicrobial activity against Staphylococcus aureus at 37 degC after 24 hrs by tube dilution method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID352318Antimicrobial activity against Bacillus subtilis at 37 degC after 24 hrs by tube dilution method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID1372212Induction of QR1 activity in mouse Hepa-1c1c7 cells assessed as induction ratio at 50 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.
AID755670Antibacterial activity against Bacillus cereus after 24 hrs by agar dilution method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID755671Antibacterial activity against Staphylococcus albus after 24 hrs by agar dilution method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID755683Antioxidant activity assessed as superoxide radical anion scavenging activity by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID38394Inhibitory potency to aminopyrine N-demethylase activity (P450) in hepatic microsomes from phenobarbitone-induced rats.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID1359153Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 50 uM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis, anionophoric activity and apoptosis-inducing bioactivity of benzimidazolyl-based transmembrane anion transporters.
AID1359155Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 50 uM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis, anionophoric activity and apoptosis-inducing bioactivity of benzimidazolyl-based transmembrane anion transporters.
AID1130739Anthelmintic activity against Hymenolepis nana infected in sheep assessed as reduction of fecal egg count at 50 mg/kg, po measured up to 7 days relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiparasitic agents. 3. Synthesis and anthelmintic activities of novel 2-pyridinyl-5-isothiocyanatobenzimidazoles.
AID755682Antioxidant activity assessed as hydroxyl radical scavenging activity after 1 hr by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID352322Octanol-water partition coefficient, log P of the compound2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID24235Partition coefficient (logP)1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID49060Response ratio = (percent increase to drug)/(percent increase to 10 E-5 M isoproterenol)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID161099Inhibition of phosphorylation of a random glutamate/tyrosine copolymer in lysates of transfected Sf9 insect cells overexpressing mouse platelet-derived growth factor receptor beta1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
AID1130735Nematocidal activity against Nematospiroides dubius infected in CF1 mouse assessed as clearance of worm burden at 0.2% dosed through diet for 4 days dosed 16 days post infection by press-plate technique1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiparasitic agents. 3. Synthesis and anthelmintic activities of novel 2-pyridinyl-5-isothiocyanatobenzimidazoles.
AID352320Antifungal activity against Candida albicans at 37 degC after 48 hrs by tube dilution method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID73439Inhibition of phosphorylation of a random glutamate/tyrosine copolymer in lysates of transfected Sf9 insect cells overexpressing human fibroblast growth factor receptor 11998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
AID1359156Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 50 uM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis, anionophoric activity and apoptosis-inducing bioactivity of benzimidazolyl-based transmembrane anion transporters.
AID755674Antibacterial activity against Escherichia coli after 24 hrs by agar dilution method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID1282094Inhibition of LPS induced NF-kappa-B transcriptional activity in mouse RAW264.7 cells after 20 hrs by SEAP reporter assay2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB.
AID352319Antimicrobial activity against Escherichia coli at 37 degC after 24 hrs by tube dilution method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID1282093Inhibition of LPS induced NF-kappa-B transcriptional activity in mouse RAW264.7 cells at 30 uM after 20 hrs by SEAP reporter assay2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Exploration of 2-benzylbenzimidazole scaffold as novel inhibitor of NF-κB.
AID59489Compound tested for contractility in anesthetized dog when administered intravenously; NT=Not tested1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID49059Response ratio = (percent increase to drug)/(percent increase to 10 E-4 M isoproterenol)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID1359154Cytotoxicity against human A549 cells assessed as reduction in cell viability at 50 uM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis, anionophoric activity and apoptosis-inducing bioactivity of benzimidazolyl-based transmembrane anion transporters.
AID755673Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by agar dilution method2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID1372210Inhibition of CYP19A1 (unknown origin) at 50 uM preincubated with NADPH followed by DBF substrate addition after 30 mins by fluorescence based assay relative to control2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.
AID755681Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
AID352321Antifungal activity against Aspergillus niger at 25 degC after 7 days by tube dilution method2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones.
AID755669Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (11.76)18.7374
1990's2 (5.88)18.2507
2000's8 (23.53)29.6817
2010's17 (50.00)24.3611
2020's3 (8.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.48 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]